Regeneron Pharmaceuticals Inc (Regeneron) discovers, develops, manufactures, and markets pharmaceutical products for the treatment of medical conditions related to cancer, eye diseases, inflammatory diseases, pain, cardiovascular and metabolic diseases, rare diseases, hematologic conditions, infectious diseases, and allergies. It develops products and product candidates based on the proprietary technology platform VelociSuite (comprising VelociGene, VelociMouse, VelocImmune, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies) designed to find specific proteins of therapeutic interest for a certain disease.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Regeneron conducts R&D to develop drugs for the treatment of serious medical conditions, including cancer, ophthalmic conditions, asthma, rheumatoid arthritis, pain, immunology & inflammation, solid organ oncology, hematology, atopic dermatitis, infectious diseases and general medicine. As of December 31, 2023, the company had antibodies in clinical trials across multiple therapeutic areas (discovered in its research laboratories) under clinical development. All these antibodies are generated using its VelociSuite technology. It includes VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. These technologies find application in various operations such as for the replacement of mouse immunoglobulin gene loci, manipulation of very large sequences of DNA, to generate mice from embryonic stem cells, rapid screening of antibodies and rapid generation of expression cell lines, for the development of potential drug candidates such as bispecific antibodies, for expanding capabilities of drug discovery cell-mediated immunity and therapeutic TCRs of oncology and to test human therapeutics against human immune cells. The company's subsidiary, Regeneron Genetics Center LLC, is responsible for conducting research and development activities aimed at expanding the utilization of human genetics and driving innovation in the design of clinical care. It also entered more than 100 collaborations with University of Colorado, Geisinger Health System, Mayo Clinic, University of Pennsylvania, UCLA Medical Center, UK Biobank, University of Oxford, University of Cambridge, and the University of Helsinki for purposes of genomic research. In FY2023, the company’s R&D expenses amounted to US$4,439 million, which as a percentage of revenue stood at 33.8%. The patent portfolio includes granted and pending patent applications covering VelociSuite technologies. The company’s patent portfolio also includes issued patents and pending applications regarding commercialized products and its product candidates in clinical development.